Project Grant R21CA317270
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $436K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded Weill Medical College of Cornell University $465,595 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to investigate immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapies. The project, titled R21CA307817, addresses a serious complication of CAR T-cell treatment for refractory B-cell malignancies. ICANS manifests as cognitive impairment and cerebral edema and remains poorly understood, limiting...
- The National Cancer Institute awarded $435,243 to Weill Medical College of Cornell University on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate GSK3 relocalizing peptides as anti-cancer therapeutics. The recipient will assess the anti-cancer efficacy of GSK3 RNLS-peptide both as a standalone therapy and in combination with the chemotherapeutic agent 5-fluorouracil. The work employs multiple orthotopic mouse models of lung, brain, and colorectal...
- The National Cancer Institute awarded Weill Medical College of Cornell University $733,149 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate immune-related adverse events (IRAE) driven by anti-PD1 immunotherapy in cancer patients. The research integrates patient-centered clinical investigation with advanced omics pipelines using human specimens, leveraging a multidisciplinary approach spanning human and mouse tissue and tumor immunology. The...
- The National Cancer Institute awarded $413,339 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on chimeric antigen receptor (CAR) T-cell therapy for lymphoma treatment. The research aligns T-cell biology with CAR architecture to enhance lymphoma therapy, addressing the limitation that durable responses are achieved in only 35–50% of lymphoma patients currently...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute awarded Weill Medical College of Cornell University $694,133 on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how sympathetic nervous system axons control melanoma progression and interact with immune effectors in the tumor microenvironment. The research focuses on defining the role of sympathetic axons in inhibiting melanoma growth through norepinephrine signaling via adrenergic receptors on immune cells, particularly...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute awarded New York University $723,777 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop peptide-centric CAR T cell immunotherapies targeting the PRAME cancer-testis antigen across multiple tumor types and HLA allotypes. The research builds on the recipient's prior work with PC-CAR T cells to address fundamental barriers limiting immunotherapy reach: tumor antigen knowledge, HLA restriction, manufacturing complexity, and receptor...
- The National Cancer Institute awarded The Washington University $548,528 under the Cancer Treatment Research program (CFDA 93.395) on September 3, 2026, to enhance CAR-T cell therapy for relapsed or refractory large B cell lymphoma. The recipient will conduct a Phase 1B clinical trial evaluating early and repeated dosing schedules of NT-I7, a long-acting interleukin-7 therapeutic, administered following axicabtagene ciloleucel or lisocabtagene maraleucel infusion in patients with relapsed or...